Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 2, 2012, Pages 341-346

  Morishita, Masanari ^a   Sumi, Toshiyuki ^a   Nakano, Yusuke ^a   Teramae, Masatomo ^a   Fukuda, Takeshi ^a   Nobeyama, Hiroyuki ^a   Yoshida, Hiroyuki ^a   Matsumoto, Yoshinari ^a   Yasui, Tomoyo ^a   Ishiko, Osamu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Mitotic arrest deficiency 2; Neoadjuvant chemotherapy; Uterine cervical cancer

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN MAD2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LOCALLY ADVANCED UTERINE CERVIX CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR BIOPSY; UTERINE CERVIX CANCER;

EID: 84855384256     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.407     Document Type: Article

References (39)

1. Li R and Murray AW: Feedback control of mitosis in budding yeast. Cell 66: 519-531, 1991.
2. Li Y and Benezra R: Identification of a human mitotic checkpoint gene: hsMAD2. Science 274: 246-248, 1996.
3. Lopez-Girona A, Furnari B, Mondesert O and Russell P: Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397: 172-175, 1999.
4. Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL and Tsao SW: Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 62: 1662-1668, 2002.
5. Orr-Weaver T and Weinberg RA: A checkpoint on the road to cancer. Nature 392: 223-224, 1998.
6. Yoon DS, Wersto RP, Zhou W, Chrest FJ, Garret ES, Kwon TK and Gabrielson E: Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 161: 391-397, 2002.
7. Lengauer C, Kinzler KW and Vogelstein B: Genetic instability in colorectal cancers. Nature 386: 623-627, 1997.
8. Lengauer C, Kinzler KW and Vogelstein B: Genetic instability in human cancers. Nature 396: 643-649, 1998.
9. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW and Benezra R: Mad2 overex-pression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11: 9-23, 2007.
10. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
11. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, Van De Rijn M, Botstein D and Brown PO: gene expression patterns in human liver cancers. Mol Biol Cell 13: 1929-1939, 2002.
12. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, Van de Rijn M, Rosen GD, Perou CM, Whyte RI, et al:Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784-13789, 2001.
13. Li GQ, Li H and Zhang HF: Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 9: 1972-1975, 2003.
14. Li GQ and Zhang HF: Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 10: 3218-3220, 2004.
15. Zhang SH, Xu AM, Chen XF, Li DH, Sun MP and Wang YJ: Clinicopathologic significance of mitotic arrest defective protein2 overexpression in hepatocellular carcinoma. Hum Pathol 39: 1827-1834, 2008.
16. Wang L, Yin F, Du Y, Du W, Chen B, Zhang Y, Wu K, Ding J, Liu J and Fan D: MAD2 as a key component of mitotic checkpoint: A probable prognostic factor for gastric cancer. Am J Clin Pathol 131: 793-801, 2009.
17. Tanaka K, Nishioka J, Kato K, Nakamura A, Mouri T, Miki C, Kusunoki M and Nobori T: Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancer. Jpn J Cancer Res 92: 952-958, 2001.
18. Yu L, Guo WC, Zhao SH, Tang J and Chen JL: Mitotic arrest defective protein 2 expression abnormality and its clinicopath-ologic significance in human osteosarcoma. APMS 118: 222-229, 2010.
19. Wu CW, Chi CW and Huang TS: Elevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer. World J gastroenterol 10: 3240-3244, 2004.
20. Sotillo R, Schvartzman JM, Socci ND and Beneztra R: Mad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawal. Nature 464: 436-440, 2010.
21. Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK, Liu Y and Tsao SW: Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopha-ryngeal carcinoma cells. Carcinogenesis 12: 2293-2297, 2000.
22. Fung MK, Cheung HW, Ling MT, Cheung AL, Wong YC and Wang X: Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells. Br J Cancer 95: 475-484, 2006.
23. Cheung HW, Chun AC, Wang Q, Deng W, Hu L, Guan XY, Nicholls JM, Ling MT, Chuan Wong Y, Tsao SW, Jin DY and Wang X: Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res 66: 4357-4367, 2006.
24. Japan Society of Gynecologic Oncology: Formulation Committee of the Treatment Guidelines for Cervical Cancer, 2007.
25. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology - Cervical Cancer - Version I, 2012.
26. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340: 1137-1143, 1999.
27. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22: 872-880, 2004.
28. Ishiko O, Sumi T, Yasui T, Matsumoto Y, Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R: Balloon-occluded arterial infusion chemotherapy, simple total hysterectomy, and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervix. Oncol Rep 7: 141-144, 2000.
29. Sardi JE, Giaroli A, Sananes CE, Gomez Rueda N, Vighi S, Ferreira M, Bastardas ML, Paniceres G and Di Paola G: Randomized trial with neoadjuvant in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic management. Int J Gynecol Cancer 6: 85-93, 1996.
30. Souhami L, Gil RA, Allan SE, Canary PC, Araujo CM, Pinto LH and Silveria TR: A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 9: 970-977, 1991.
31. Tattersall MH, Lorvidhaya V, Vootiprux V, Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A and Yen MS: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol 13: 444-451, 1995.
32. Ishiko O, Sumi T, Yasui T, Matsumoto Y, Ogita S, Kaminou T, Nakamura K and Yamada R: Tumor marker and MR imaging criteria for evaluating the efficacy of cyclic balloon-occluded arterial infusion for advanced cancer of the uterine cervix. Oncol Rep 4: 827-830, 2000.
33. Ishiko O, Sumi T, Yoshida H, Ogita S and Yamada R: Expression of apoptosis regulatory proteins in advanced cancer of the uterine cervix after cyclic balloon-occluded arterial infusion chemotherapy. Int J Oncol 6: 1151-1155, 2001.
34. Nobeyama H, Sumi T, Misugi F, Okamoto E, Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K and Ishiko O: Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer. Int J Mol Med 1: 101-105, 2004.
35. Okamoto E, Sumi T, Misugi F, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K and Ishiko O: Expression of apoptosis-related proteins in advanced uterine cervical cancer after balloon-occluded arterial infusion chemotherapy as an indicator of the efficiency of this therapy. Int J Mol Med 1: 41-47, 2005.
36. Tsuji K, Yamada R, Kawabata M, Mitsuzane K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon occluded arterial infusion of anticancer drugs on the prognosis of cervical cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 32: 1337-1345, 1995.
37. Sironi S, Belloni C, Taccagni G and Del Maschio A: Invasive cervical carcinoma: MR imaging after prospective chemotherapy. Radiology 180: 719-722, 1991.
38. Kim KH, Lee BH, Do YS, Chin SY and Kim BG: Stage IIb cervical carcinoma: MR evaluation of intraarterial chemotherapy. Radiology 192: 61-65, 1994.
39. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.